Industry News
Pharmaceutical Industry News

In their high-profile competition…
In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with Novo Nordisk. On Friday, Lilly checked another item off that list as it secured FDA
Biogen highlighted patient…
Biogen highlighted patient advocate and content creator Naomi Rose’s story living with cutaneous lupus erythematosus (CLE) on its social media platforms.
Omnicom’s maslansky + partners…
Omnicom’s maslansky + partners has expanded its leadership team, hiring two new partners and expanding the role of a founding partner to strengthen its healthcare and life science practice.
Stephen Farquhar has taken over as…
Stephen Farquhar has taken over as CEO of Publicis Health Media (PHM), succeeding longtime Publicis executive Andrea Palmer.
Though not without a bump along…
Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease.
Roche is taking a less-trodden…
Roche is taking a less-trodden path in obesity. Akeso CEO counters concerns over shrinking lung cancer data for ivonescimab. A U.S. congressman says China is "beating us on our ground game" in biotech. Plus more.
Cytokinetics’ cardiac myosin…
Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningful benefits in patients with a rare heart condition called non-obstructive hypertrophic cardiomyopathy. An approval for this indication could potentially double the pool
Bristol Myers Squibb will spend…
Bristol Myers Squibb will spend $173 million to build a second radiopharmaceutical manufacturing facility in Indiana to couple with its current site in Indianapolis. The new plant will be in nearby Whitestown.
Ajaz Khan, M.D., a medical…
Ajaz Khan, M.D., a medical oncologist at City of Hope Chicago, was in the packed audience at this summer’s American Society of Clinical Oncology meeting when Revolution Medicines received a standing ovation for its groundbreaking
In the latest in a string of…
In the latest in a string of setbacks in biopharma’s efforts to fight Medicare drug price negotiations, a lawsuit from the industry’s top lobbying group has been rejected at the appeals level.
Amgen and AstraZeneca’s…
Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis as the partners eye another challenge to Sanofi and Regeneron’s incumbent Dupixent.
Labcorp’s Catie Schlechter…
Labcorp's Catie Schlechter discusses how sponsors are using real-world data to improve trial design, recruitment and strategy.
New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many
Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more.
Artis BioSolutions opened the…
Artis BioSolutions opened the doors to a new manufacturing center located in Bilbao, Spain, that expands the CDMO’s production capabilities in next-generation genetic medicines.
The Trump administration will…
The Trump administration will soon unveil most favored nation drug pricing deals with several mid-sized biopharma companies, according to a report from Bloomberg. The announcement is expected on Monday.
Since its immunology scholarship…
Since its immunology scholarship was established in 2016, AbbVie has supported more than 350 students living with immunology conditions, with its investments in the program totaling more than $6 million.
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
As AI reshapes health discovery,…
As AI reshapes health discovery, GoodRx is helping pharma turn consumer and HCP questions into action.
Some 20 years after helping…
Some 20 years after helping introduce the first once-daily single-tablet HIV regimen, Gilead Sciences has crossed the regulatory finish line with a new oral treatment option in the U.S.
Following dynamite data that…
Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for the treatment of metastatic pancreatic


